Phase II placebo-controlled study of nepafenac ophthalmic suspension 0.1% for postoperative inflammation and ocular pain associated with cataract surgery in Japanese patients

Journal of Ophthalmic Inflammation and Infection

Table 4 Demographic data (ITT)

	Total		Nepafenac group		Placebo group		P value^a
	N	%	N	%	N	%	P value^a
Total	211	100.0	106	50.2	105	49.8
Gender
Male	98	46.4	49	46.2	49	46.7	0.9489
Female	113	53.6	57	53.8	56	53.3	0.9489
Age
18 to 64 years	59	28.0	24	22.6	35	33.3	0.0836
≥ 65 years	152	72.0	82	77.4	70	66.7	0.0836
Emery’s classification
1	50	23.7	28	26.4	22	21.0	0.3508
2	161	76.3	78	73.6	83	79.0	0.3508